drugset / Trial / NCT06034002
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Timeline
- Start
- 2023-12-04
- Primary completion
- 2028-10-29
- Completion
- 2028-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCA033989 | Unknown | — | — |
| Subject | Ruxolitinib | Small molecule | — | — |